Public markets activity included CytomX’s $250 million follow‑on offering, executed after positive Phase I data for its EpCAM ADC varsetatug masetecan showing a 32% objective response rate in colorectal cancer. CytomX said proceeds will fund ongoing trials, including a Phase Ib/II chemo combination planned this year. The financing priced at a discount and left the stock trading near pre‑announcement levels. The financing snapshot also flagged Alto and other biotechs raising capital to sustain clinical development, reflecting continued investor appetite for companies that can de‑risk programs with clinical signals.